Edarbyclor
NDC Package 75929-230-03

11-digit billing NDC: 75929023003

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure.Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy.Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Marketed by Pharma Packaging Solutions, Llc Dba Tjoapack Llc, this product is identified by NDC 75929-230 and is authorized under FDA application NDA202331.

Identification & Billing

NDC Package Code
75929-230-03
Package Description
30 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
75929023003

Clinical Specifications

Proprietary Name
Edarbyclor
Dosage Form
-
Usage Information
Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure.Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy.Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor.Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor.Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk.Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14)] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails.Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg.

Regulatory & Marketing

Labeler Name
Pharma Packaging Solutions, Llc Dba Tjoapack Llc
FDA Application #
NDA202331
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-01-2013
End Marketing Date
07-27-2026
Listing Expiration
07-27-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 75929-230-03 identifies a specific commercial package of 30 tablet in 1 bottle of Edarbyclor, labeled by Pharma Packaging Solutions, Llc Dba Tjoapack Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Pharma Packaging Solutions, Llc Dba Tjoapack Llc on February 01, 2013. The current certification is valid through July 27, 2026.

How is this Pharma Packaging Solutions, Llc Dba Tjoapack Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 75929023003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
75929-230-03
11-Digit CMS (5-4-2)
75929-0230-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.